TY - JOUR
T1 - Nationwide Outbreak of Candida auris Infections Driven by COVID-19 Hospitalizations, Israel, 2021–2022
AU - Biran, Roni
AU - Cohen, Regev
AU - Finn, Talya
AU - Brosh-Nissimov, Tal
AU - Rahav, Galia
AU - Yahav, Dafna
AU - Amit, Sharon
AU - Shachor-Meyouhas, Yael
AU - Atamna, Alaa
AU - Bishara, Jihad
AU - Ashkenazi-Hoffnung, Liat
AU - Zvi, Haim Ben
AU - Hershman-Sarafov, Mirit
AU - Maayan, Shlomo
AU - Maor, Yasmin
AU - Schwartz, Orna
AU - Zimhony, Oren
AU - Lellouche, Jonathan
AU - Elbaz, Meital
AU - Burdelova, Ela
AU - Mizrahi, Naama
AU - Novikov, Anna
AU - Henig, Oryan
AU - Ben-Ami, Ronen
N1 - Publisher Copyright:
© 2023 Centers for Disease Control and Prevention (CDC). All rights reserved.
PY - 2023/7
Y1 - 2023/7
N2 - We report an outbreak of Candida auris across multiple healthcare facilities in Israel. For the period of May 2014–May 2022, a total of 209 patients with C. auris infection or colonization were identified. The C. auris incidence rate increased 30-fold in 2021 (p = 0.00015), corresponding in time with surges of COVID-19–related hospitalization. Multilocus sequence typing revealed hospital-level outbreaks with distinct clones. A clade III clone, imported into Israel in 2016, accounted for 48.8% of typed isolates after January 2021 and was more frequently resistant to fluconazole (100% vs. 63%; p = 0.00017) and voriconazole (74% vs. 5.2%; p<0.0001) than were non–clade III isolates. A total of 23% of patients had COVID-19, and 78% received mechanical ventilation. At the hospital level, outbreaks initially involved mechanically ventilated patients in specialized COVID-19 units and then spread sequentially to ventilated non–COVID-19 patients and nonventilated patients.
AB - We report an outbreak of Candida auris across multiple healthcare facilities in Israel. For the period of May 2014–May 2022, a total of 209 patients with C. auris infection or colonization were identified. The C. auris incidence rate increased 30-fold in 2021 (p = 0.00015), corresponding in time with surges of COVID-19–related hospitalization. Multilocus sequence typing revealed hospital-level outbreaks with distinct clones. A clade III clone, imported into Israel in 2016, accounted for 48.8% of typed isolates after January 2021 and was more frequently resistant to fluconazole (100% vs. 63%; p = 0.00017) and voriconazole (74% vs. 5.2%; p<0.0001) than were non–clade III isolates. A total of 23% of patients had COVID-19, and 78% received mechanical ventilation. At the hospital level, outbreaks initially involved mechanically ventilated patients in specialized COVID-19 units and then spread sequentially to ventilated non–COVID-19 patients and nonventilated patients.
UR - http://www.scopus.com/inward/record.url?scp=85164040144&partnerID=8YFLogxK
U2 - 10.3201/eid2907.221888
DO - 10.3201/eid2907.221888
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 37347492
AN - SCOPUS:85164040144
SN - 1080-6040
VL - 29
SP - 1302
EP - 1311
JO - Emerging Infectious Diseases
JF - Emerging Infectious Diseases
IS - 7
ER -